475-97 Search Results


mouse obestatin  (Echelon Biosciences)
92
Echelon Biosciences mouse obestatin
The thickness of the bar indicates the intensities of the NOEs for the following peptides: (A) human <t>obestatin</t> ( 1 ), (B) human non-amidated obestatin ( 2 ), (C) human (6–23)-obestatin ( 3 ), (D) human (11–23)-obestatin ( 4 ), (E) human (16–23)-obestatin ( 5 ) and (F) mouse obestatin ( 6 ). The asterisk (*) represents the C-terminal amidation of the molecule. The dagger (#) represents the differences between human obestatin ( 1 ) and mouse obestatin ( 6 ).
Mouse Obestatin, supplied by Echelon Biosciences, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse obestatin/product/Echelon Biosciences
Average 92 stars, based on 1 article reviews
Price from $9.99 to $1999.99
mouse obestatin - by Bioz Stars, 2024-12
92/100 stars
  Buy from Supplier
pcdna3 1 mpmca4b plasmid 47597  (Addgene inc)
N/A
Standard format Plasmid sent in bacteria as agar stab
   Buy from Supplier

Image Search Results


The thickness of the bar indicates the intensities of the NOEs for the following peptides: (A) human obestatin ( 1 ), (B) human non-amidated obestatin ( 2 ), (C) human (6–23)-obestatin ( 3 ), (D) human (11–23)-obestatin ( 4 ), (E) human (16–23)-obestatin ( 5 ) and (F) mouse obestatin ( 6 ). The asterisk (*) represents the C-terminal amidation of the molecule. The dagger (#) represents the differences between human obestatin ( 1 ) and mouse obestatin ( 6 ).

Journal: PLoS ONE

Article Title: The NMR Structure of Human Obestatin in Membrane-Like Environments: Insights into the Structure-Bioactivity Relationship of Obestatin

doi: 10.1371/journal.pone.0045434

Figure Lengend Snippet: The thickness of the bar indicates the intensities of the NOEs for the following peptides: (A) human obestatin ( 1 ), (B) human non-amidated obestatin ( 2 ), (C) human (6–23)-obestatin ( 3 ), (D) human (11–23)-obestatin ( 4 ), (E) human (16–23)-obestatin ( 5 ) and (F) mouse obestatin ( 6 ). The asterisk (*) represents the C-terminal amidation of the molecule. The dagger (#) represents the differences between human obestatin ( 1 ) and mouse obestatin ( 6 ).

Article Snippet: Human obestatin ( 1 ) and mouse obestatin ( 6 ) were obtained from California Peptide Research Inc. (Napa, CA, US).

Techniques:

Structural statistics for the ensemble of the best 20 structures of human obestatin (1), its fragments and mouse obestatin (6).

Journal: PLoS ONE

Article Title: The NMR Structure of Human Obestatin in Membrane-Like Environments: Insights into the Structure-Bioactivity Relationship of Obestatin

doi: 10.1371/journal.pone.0045434

Figure Lengend Snippet: Structural statistics for the ensemble of the best 20 structures of human obestatin (1), its fragments and mouse obestatin (6).

Article Snippet: Human obestatin ( 1 ) and mouse obestatin ( 6 ) were obtained from California Peptide Research Inc. (Napa, CA, US).

Techniques:

(A) Human obestatin ( 1 ), (B) human non-amidated obestatin ( 2 ), (C) human (6–23)-obestatin ( 3 ), (D) human (11–23)-obestatin ( 4 ), (E) human (16–23)-obestatin ( 5 ) and (F) mouse obestatin ( 6 ). The Tyr16 side chain is shown in blue.

Journal: PLoS ONE

Article Title: The NMR Structure of Human Obestatin in Membrane-Like Environments: Insights into the Structure-Bioactivity Relationship of Obestatin

doi: 10.1371/journal.pone.0045434

Figure Lengend Snippet: (A) Human obestatin ( 1 ), (B) human non-amidated obestatin ( 2 ), (C) human (6–23)-obestatin ( 3 ), (D) human (11–23)-obestatin ( 4 ), (E) human (16–23)-obestatin ( 5 ) and (F) mouse obestatin ( 6 ). The Tyr16 side chain is shown in blue.

Article Snippet: Human obestatin ( 1 ) and mouse obestatin ( 6 ) were obtained from California Peptide Research Inc. (Napa, CA, US).

Techniques:

(A) Immunocytochemical detection of GPR39 in ARPE-19 cells (objective magnification of 20x). (B) The effect of siRNA depletion of GPR39 on pAkt(S473) and pERK1/2(T202/Y204) in ARPE-19 cells after human obestatin treatment ( 1 , 100 nM, 10 min). The ARPE-19 cells were transfected with GPR39 siRNA prior to obestatin 1 treatment. Equal amounts of protein in each sample were used to assess the expression of GPR39 by western blotting. The GPR39 level was expressed as the fold change relative to the control siRNA-transfected cells (mean ± SE). The protein expression was normalized relative to actin. The data are expressed as the mean ± SE. The asterisk (*) denotes P <0.05 when comparing the treated control siRNA group with the control siRNA group; the dagger (#) denotes P <0.05 when comparing the GPR39 siRNA group with the control siRNA group.

Journal: PLoS ONE

Article Title: The NMR Structure of Human Obestatin in Membrane-Like Environments: Insights into the Structure-Bioactivity Relationship of Obestatin

doi: 10.1371/journal.pone.0045434

Figure Lengend Snippet: (A) Immunocytochemical detection of GPR39 in ARPE-19 cells (objective magnification of 20x). (B) The effect of siRNA depletion of GPR39 on pAkt(S473) and pERK1/2(T202/Y204) in ARPE-19 cells after human obestatin treatment ( 1 , 100 nM, 10 min). The ARPE-19 cells were transfected with GPR39 siRNA prior to obestatin 1 treatment. Equal amounts of protein in each sample were used to assess the expression of GPR39 by western blotting. The GPR39 level was expressed as the fold change relative to the control siRNA-transfected cells (mean ± SE). The protein expression was normalized relative to actin. The data are expressed as the mean ± SE. The asterisk (*) denotes P <0.05 when comparing the treated control siRNA group with the control siRNA group; the dagger (#) denotes P <0.05 when comparing the GPR39 siRNA group with the control siRNA group.

Article Snippet: Human obestatin ( 1 ) and mouse obestatin ( 6 ) were obtained from California Peptide Research Inc. (Napa, CA, US).

Techniques: Transfection, Expressing, Western Blot

Immunocytochemical analysis of the Ki67 expression in ARPE-19 cells after 24 h of proliferation. A) Control. B) 10% FBS (v/v). C) 100 nM human obestatin ( 1 ). D) 100 nM human non-amidated obestatin ( 2 ). E) 100 nM human (6–23)-obestatin ( 3 ). F) 100 nM human (11–23)-obestatin ( 4 ). G) 100 nM human (16–23)-obestatin ( 5 ). H) 100 nM mouse obestatin ( 6 ). The magnification was 20x. I) Quantification of the immunocytochemical expression of Ki67 in ARPE-19 cells after treatment with 10% FBS (v/v; 100±2), 100 nM human obestatin ( 1 ; 84±1%), 100 nM human non-amidated obestatin ( 2 ; 33±2%), 100 nM human (6–23)-obestatin ( 3 ; 56±3%), 100 nM human (11–23)-obestatin ( 4 ; 67±3%), 100 nM human (16–23)-obestatin ( 5 ; 50±2%) and 100 nM mouse obestatin ( 6 ; 32±2%). The expression of Ki67 was expressed as the fold change relative to the expression level in FBS-treated cells in the positive control (mean ± SE). J) BrdU incorporation in ARPE-19 cells after treatment with 10% FBS (v/v; 100±1), 100 nM human obestatin ( 1 ; 84±4%), 100 nM human non-amidated obestatin ( 2 ; 39±2%), 100 nM human (6–23)-obestatin ( 3 ; 30±1%), 100 nM human (11–23)-obestatin ( 4 ; 52±3%), 100 nM human (16–23)-obestatin ( 5 ; 34±3%) and 100 nM mouse obestatin ( 6 ; 35±1%). The BrdU incorporation was expressed as the fold change relative to the level in FBS-treated cells in the positive control (mean ± SE). The data are expressed as the mean ± SE. The asterisk (*) denotes P <0.05 when comparing the peptide-treated ARPE-19 cells groups with the human obestatin ( 1 )-treated group.

Journal: PLoS ONE

Article Title: The NMR Structure of Human Obestatin in Membrane-Like Environments: Insights into the Structure-Bioactivity Relationship of Obestatin

doi: 10.1371/journal.pone.0045434

Figure Lengend Snippet: Immunocytochemical analysis of the Ki67 expression in ARPE-19 cells after 24 h of proliferation. A) Control. B) 10% FBS (v/v). C) 100 nM human obestatin ( 1 ). D) 100 nM human non-amidated obestatin ( 2 ). E) 100 nM human (6–23)-obestatin ( 3 ). F) 100 nM human (11–23)-obestatin ( 4 ). G) 100 nM human (16–23)-obestatin ( 5 ). H) 100 nM mouse obestatin ( 6 ). The magnification was 20x. I) Quantification of the immunocytochemical expression of Ki67 in ARPE-19 cells after treatment with 10% FBS (v/v; 100±2), 100 nM human obestatin ( 1 ; 84±1%), 100 nM human non-amidated obestatin ( 2 ; 33±2%), 100 nM human (6–23)-obestatin ( 3 ; 56±3%), 100 nM human (11–23)-obestatin ( 4 ; 67±3%), 100 nM human (16–23)-obestatin ( 5 ; 50±2%) and 100 nM mouse obestatin ( 6 ; 32±2%). The expression of Ki67 was expressed as the fold change relative to the expression level in FBS-treated cells in the positive control (mean ± SE). J) BrdU incorporation in ARPE-19 cells after treatment with 10% FBS (v/v; 100±1), 100 nM human obestatin ( 1 ; 84±4%), 100 nM human non-amidated obestatin ( 2 ; 39±2%), 100 nM human (6–23)-obestatin ( 3 ; 30±1%), 100 nM human (11–23)-obestatin ( 4 ; 52±3%), 100 nM human (16–23)-obestatin ( 5 ; 34±3%) and 100 nM mouse obestatin ( 6 ; 35±1%). The BrdU incorporation was expressed as the fold change relative to the level in FBS-treated cells in the positive control (mean ± SE). The data are expressed as the mean ± SE. The asterisk (*) denotes P <0.05 when comparing the peptide-treated ARPE-19 cells groups with the human obestatin ( 1 )-treated group.

Article Snippet: Human obestatin ( 1 ) and mouse obestatin ( 6 ) were obtained from California Peptide Research Inc. (Napa, CA, US).

Techniques: Expressing, Positive Control, BrdU Incorporation Assay